Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:temple
gptkb:Glaxo_Smith_Kline gptkb:Novartis |
| gptkbp:class |
BRAF inhibitor
|
| gptkbp:clinical_trial |
NC T01358075
NC T01677741 NC T02019533 NC T02159066 NC T02224781 |
| gptkbp:contraindication |
pregnancy
breastfeeding severe liver impairment hypersensitivity to dabrafenib |
| gptkbp:dosage_form |
150 mg
300 mg |
| gptkbp:effective_date |
2013-05-29
|
| gptkbp:form |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tafinlar
|
| gptkbp:ingredients |
gptkb:dabrafenib
|
| gptkbp:interacts_with |
gptkb:warfarin
CY P2 C19 inhibitors CY P3 A4 inducers other BRAF inhibitors |
| gptkbp:is_atype_of |
L01 X E30
|
| gptkbp:is_monitored_by |
cardiac function
skin reactions liver function blood counts |
| gptkbp:is_used_for |
treatment of melanoma
treatment of non-small cell lung cancer |
| gptkbp:label |
contains dosage instructions
contains patient information leaflet contains side effects information contains storage instructions |
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:Novartis
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Australia gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:packaging |
gptkb:beer
blister pack |
| gptkbp:requires |
gptkb:theorem
|
| gptkbp:side_effect |
fatigue
headache nausea fever vomiting diarrhea rash joint pain |
| gptkbp:social_structure |
C23 H28 F3 N5 O3 S
|
| gptkbp:storage |
room temperature
keep out of reach of children protected from moisture |
| gptkbp:type_of_care |
important for efficacy
|